Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects

Journal of General Physiology

Volumn 144, Issue 4, 2014, Pages 321-336

  Csanády, László ^a   Töröcsik, Beáta ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

5-NITRO-2-(3-PHENYLPROPYLAMINO)BENZOIC ACID; ADENOSINE TRIPHOSPHATE; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; NITROBENZOIC ACID DERIVATIVE;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BINDING SITE; CHANNEL GATING; DRUG EFFECTS; KINETICS; METABOLISM; OOCYTE; PATCH CLAMP TECHNIQUE; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHLORIDE CHANNELS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ION CHANNEL GATING; KINETICS; NITROBENZOATES; OOCYTES; PATCH-CLAMP TECHNIQUES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 84908227848     PISSN: 00221295     EISSN: 15407748     Source Type: Journal    
DOI: 10.1085/jgp.201411246     Document Type: Article

References (36)

1. Ahern, C.A., A.L. Eastwood, D.A. Dougherty, and R. Horn. 2009. An electrostatic interaction between TEA and an introduced pore aromatic drives spring-in-the-door inactivation in Shaker potassium channels. J. Gen. Physiol. 134:461-469. http://dx.doi.org/10 .1085/jgp.200910260
2. Al-Shawi, M.K. 2011. Catalytic and transport cycles of ABC exporters. Essays Biochem. 50:63-83. http://dx.doi.org/10.1042/bse0500063
3. Aleksandrov, L., A.A. Aleksandrov, X.B. Chang, and J.R. Riordan. 2002. The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover. J. Biol. Chem. 277:15419-15425. http://dx.doi.org/10.1074/jbc.M111713200
4. Basso, C., P. Vergani, A.C. Nairn, and D.C. Gadsby. 2003. Prolonged nonhydrolytic interaction of nucleotide with CFTR's NH2-terminal nucleotide binding domain and its role in channel gating. J. Gen. Physiol. 122:333-348. http://dx.doi.org/10.1085/jgp.200308798
5. Boyle, M.P., S.C. Bell, M.W. Konstan, S.A. McColley, S.M. Rowe, E. Rietschel, X. Huang, D. Waltz, N.R. Patel, and D. Rodman; VX09- 809-102 Study Group. 2014. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir. Med. 2:527-538. http:// dx.doi.org/10.1016/S2213-2600(14)70132-8
6. Chan, K.W., L. Csanády, D. Seto-Young, A.C. Nairn, and D.C. Gadsby. 2000. Severed molecules functionally define the boundaries of the cystic fibrosis transmembrane conductance regulator's NH2- terminal nucleotide binding domain. J. Gen. Physiol. 116:163-180. http://dx.doi.org/10.1085/jgp.116.2.163
7. Cheng, S.H., R.J. Gregory, J. Marshall, S. Paul, D.W. Souza, G.A. White, C.R. O'Riordan, and A.E. Smith. 1990. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 63:827-834. http://dx.doi.org/10 .1016/0092-8674(90)90148-8
8. Cholon, D.M., N.L. Quinney, M.L. Fulcher, C.R. Esther Jr., J. Das, N.V. Dokholyan, S.H. Randell, R.C. Boucher, and M. Gentzsch. 2014. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci. Transl. Med. 6:246ra96. http://dx.doi.org/10.1126/scitranslmed.3008680
9. Csanády, L. 2000. Rapid kinetic analysis of multichannel records by a simultaneous fit to all dwell-time histograms. Biophys. J. 78:785- 799. http://dx.doi.org/10.1016/S0006-3495(00)76636-7
10. Csanády, L., and B. Töröcsik. 2014. Catalyst-like modulation of transition states for CFTR channel opening and closing: new stimulation strategy exploits nonequilibrium gating. J. Gen. Physiol. 143:269-287. http://dx.doi.org/10.1085/jgp.201311089
11. Csanády, L., K.W. Chan, D. Seto-Young, D.C. Kopsco, A.C. Nairn, and D.C. Gadsby. 2000. Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains. J. Gen. Physiol. 116:477-500. http://dx.doi.org/ 10.1085/jgp.116.3.477
12. Csanády, L., A.C. Nairn, and D.C. Gadsby. 2006. Thermodynamics of CFTR channel gating: a spreading conformational change initiates an irreversible gating cycle. J. Gen. Physiol. 128:523-533. http://dx.doi.org/10.1085/jgp.200609558
13. - ion pore revealed by distributions of open channel burst durations. Proc. Natl. Acad. Sci. USA. 107:1241-1246. http://dx.doi.org/10.1073/pnas .0911061107
14. Dalton, J., O. Kalid, M. Schushan, N. Ben-Tal, and J. Villà-Freixa. 2012. New model of cystic fibrosis transmembrane conductance regulator proposes active channel-like conformation. J. Chem. Inf. Model. 52:1842-1853. http://dx.doi.org/10.1021/ci2005884
15. Dean, M., and T. Annilo. 2005. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6:123-142. http://dx.doi.org/10.1146/annurev.genom .6.080604.162122
16. Gadsby, D.C., P. Vergani, and L. Csanády. 2006. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 440:477-483. http://dx.doi.org/10.1038/nature04712
17. Gunderson, K.L., and R.R. Kopito. 1995. Conformational states of CFTR associated with channel gating: the role ATP binding and hydrolysis. Cell. 82:231-239. http://dx.doi.org/10.1016/0092- 8674(95)90310-0
18. Hollenstein, K., R.J. Dawson, and K.P. Locher. 2007. Structure and mechanism of ABC transporter proteins. Curr. Opin. Struct. Biol. 17:412-418. http://dx.doi.org/10.1016/j.sbi.2007.07.003
19. - channel by ATP-driven nucleotide-binding domain dimerisation. J. Physiol. 587:2151-2161. http://dx.doi.org/10.1113/jphysiol.2009 .171595
20. Jih, K.Y., and T.C. Hwang. 2013. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl. Acad. Sci. USA. 110:4404-4409. http:// dx.doi.org/10.1073/pnas.1215982110
21. Jih, K.Y., Y. Sohma, and T.C. Hwang. 2012. Nonintegral stoichiometry in CFTR gating revealed by a pore-lining mutation. J. Gen. Physiol. 140:347-359. http://dx.doi.org/10.1085/jgp.201210834
22. Kopeikin, Z., Z. Yuksek, H.Y. Yang, and S.G. Bompadre. 2014. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J. Cyst. Fibros. http:// dx.doi.org/10.1016/j.jcf.2014.04.003
23. Linsdell, P. 2005. Location of a common inhibitor binding site in the cytoplasmic vestibule of the cystic fibrosis transmembrane conductance regulator chloride channel pore. J. Biol. Chem. 280: 8945-8950. http://dx.doi.org/10.1074/jbc.M414354200
24. Linsdell, P., J.A. Tabcharani, and J.W. Hanrahan. 1997. Multi-ion mechanism for ion permeation and block in the cystic fibrosis transmembrane conductance regulator chloride channel. J. Gen. Physiol. 110:365-377. http://dx.doi.org/10.1085/jgp.110.4.365
25. Miki, H., Z. Zhou, M. Li, T.C. Hwang, and S.G. Bompadre. 2010. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs. J. Biol. Chem. 285:19967-19975. http://dx.doi.org/10.1074/ jbc.M109.092684
26. Ramjeesingh, M., C. Li, E. Garami, L.J. Huan, K. Galley, Y. Wang, and C.E. Bear. 1999. Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator). Biochemistry. 38:1463-1468. http://dx.doi.org/10.1021/bi982243y
27. Ramsey, B.W., J. Davies, N.G. McElvaney, E. Tullis, S.C. Bell, P. Drevínek, M. Griese, E.F. McKone, C.E. Wainwright, M.W. Konstan, et al. VX08-770-102 Study Group. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365:1663-1672. http://dx.doi.org/10.1056/NEJMoa1105185
28. Riordan, J.R., J.M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.L. Chou, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 245:1066-1073. http:// dx.doi.org/10.1126/science.2475911
29. Tsai, M.F., M. Li, and T.C. Hwang. 2010. Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel. J. Gen. Physiol. 135:399-414. http://dx.doi.org/10.1085/jgp.201010399
30. Van Goor, F., S. Hadida, P.D.J. Grootenhuis, B. Burton, D. Cao, T. Neuberger, A. Turnbull, A. Singh, J. Joubran, A. Hazlewood, et al. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA. 106:18825- 18830. http://dx.doi.org/10.1073/pnas.0904709106
31. Van Goor, F., S. Hadida, P.D.J. Grootenhuis, B. Burton, J.H. Stack, K.S. Straley, C.J. Decker, M. Miller, J. McCartney, E.R. Olson, et al. 2011. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA. 108:18843-18848. http://dx.doi.org/10.1073/pnas.1105787108
32. Veit, G., R.G. Avramescu, D. Perdomo, P.W. Phuan, M. Bagdany, P.M. Apaja, F. Borot, D. Szollosi, Y.S. Wu, W.E. Finkbeiner, et al. 2014. Some gating potentiators, including VX-770, diminish Δ F508-CFTR functional expression. Sci. Transl. Med. 6:246ra97. http://dx.doi.org/10.1126/scitranslmed.3008889
33. - channels. J. Gen. Physiol. 121:17-36. http://dx.doi.org/10.1085/jgp.20028673
34. Vergani, P., S.W. Lockless, A.C. Nairn, and D.C. Gadsby. 2005. CFTR channel opening by ATP-driven tight dimerization of its nucleotide- binding domains. Nature. 433:876-880. http://dx.doi.org/ 10.1038/nature03313
35. Wang, W., G. Li, J.P. Clancy, and K.L. Kirk. 2005. Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs. J. Biol. Chem. 280:23622-23630. http://dx.doi .org/10.1074/jbc.M503118200
36. --channel blockers in the thick ascending limb of the loop of Henle. Structure activity relationship. Pflugers Arch. 407:S128-S141. http://dx.doi.org/10.1007/ BF00584942